Clinical, Electrocardiographic, and Cardiac Magnetic Resonance Imaging Risk Factors Associated with Ventricular Tachyarrhythmias in Nonischemic Cardiomyopathy (MARVEN Study)
-
- STATUS
- Recruiting
Summary
Implantable cardioverter defibrillator (ICD) for primary prevention of mortality is an approved therapy in ischemic and nonischemic cardiomyopathy patients with left ventricular ejection fraction (EF) ≤35%.
However, data from clinical trials leading to this indication in nonischemic cardiomyopathy (NICM) patients were limited.
- The DEFINITE [1] trial (458 patients; hazard ratio 0.65; p=0.08) and a subgroup analysis of the SCD-HeFT trial [2] (792 patients; hazard ratio = 0.73; p=0.06) showed a non-significant but clinically meaningful reduction in mortality, and significant reductions in sudden cardiac death [1] or tachyarrhythmic mortality [3].
- These findings served to form a Class I indication with the level evidence B for ICD implantation in nonischemic cardiomyopathy patients [4].
- The DANISH ICD trial (published in 2016 [5]) showed that randomized 1,116 patients with NICM and EF ≤35% to ICD or no ICD demonstrated lack of significant mortality reduction in ICD patients when compared to non-ICD patients (hazard ratio=0.87; p=0.28), but significant reduction in the risk of sudden cardiac death (hazard ratio=0.50; p=0.005).
- The DANISH patients were on optimal pharmacological therapy and 58% had CRT devices.
Consistently, DEFINITE, SCD-HeFT, and DANISH trials showed a significant reduction in sudden cardiac or tachyarrhythmia death with ICD, indicating that ICD is beneficial in groups of patients developing tachyarrhythmias that might lead to sudden cardiac death [1-5].
Description
Identification of NICM patients who are likely to develop ventricular tachyarrhythmias is challenging.
In the light of MADIT-RIT and ADVANCE III trials, modern programming of ICDs is targeting faster (188-200 bpm) and longer (>30 beats) episodes of ventricular tachyarrhythmias, that might serve as the endpoint related to a reduction in sudden cardiac death with ICDs [6, 7].
Data from the MADIT-CRT trial [8,9] in 416 NICM patients in NYHA class II with QRS ≥130 ms who were randomized to CRT-D and who had a 24-hour Holter ECG recording obtained prior to device implantation has served to develop risk stratification model for this study.
Presence of NSVT on preimplantation Holter (observed in 194 [47%] patients) was associated with hazard ratio of 3.08 (p<0.001) for fast VT≥188 bpm or VF, enlarged LVESVi >86 ml/m2 (observed in 50% of patients) with hazard ratio of 2.81 (p<0.001), and Non-LBBB QRS morphology (observed in 44 (11%) patients) with hazard ratio of 3.33 (p<0.001) in a multivariate model predicting fast VT>188 bpm or VF.
This risk prediction model utilizing Holter-detected NSVT, LBBB or Non-LBBB QRS morphology, and left ventricular volume provided effective risk stratification that could guide therapeutic decisions regarding implantation of CRT-D, CRT-P, or ICD devices in NICM heart failure patients with QRS≥120 ms, as per current CRT indications.
The above risk model will be validated in this study in 350 NICM patients with wide QRS≥120ms since data from the MADIT-CRT were acquired a decade ago.
There is an increasing interest in assessment of myocardial damage using late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) and the data are encouraging [10-15], showing about a 3-8 fold increase in the risk of SCD in patients with evident myocardial abnormalities by LGE in comparison to those without LGE.
CMR offers insight into the extent of myocardial fibrosis that, if combined with electrical markers could greatly improve identification of patients benefiting from an implantable defibrillator as well as those in whom device placement might be deferred.
Details
| Condition | Pacemaker (ICD) |
|---|---|
| Clinical Study Identifier | TX217964 |
| Last Modified on | 24 November 2020 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer